News and Media

Tchaikapharma High Quality Medicines ranks among the leaders in the Prescription Drugs (Rx) market for the past 12 months (as of June 2019).   The ranking “Top 10 Corporations in the market for prescription products” of the world’s leading analytics company IQVIA  takes into account sales at end-customer prices, with Tchaikapharma increasing its market share […]

By the end of 2018, Tchaikapharma expects to be issued with Marketing Authorizations for three new prescription drugs, which will enrich the portfolio and the well-developed therapeutic baskets of the company with the following medications and indications:   Chlorthidon (chlorthalidone) – for the treatment of arterial hypertension, essential or renovascular, or isolated systolic hypertension.   […]

Tchaikapharma completed the bioequivalence clinical trials of 4 new dual-component pharmaceutical products for the treatment of arterial hypertension and other cardiovascular diseases – with sucsess. The new drug fixed-dosage combinations with angiotensin receptor blockers and thiazide or thiazide-similar diuretics represent innovative solutions for an advanced medical care.   The researched and other already registered new […]

Pizona Combi contains pioglitazone and metformin that controls blood sugar levels. It helps the body to utilize better produced by body insulin when metformin alone is insufficient. The medicinal product is subject to medical prescription. For more details, please check section Products ATC код: A10B 02

The 33rd National Meeting of the Association of Medical Students in Bulgaria was held in Pleven from 16 to 18 March with the support of Tchaikapharma.   A specially designed booth will welcome the participants in the eighth scientific conference of the Bulgarian Cardiac and Vascular Association under the auspices of the Rector of the […]